Table 1.
Baseline characteristics of 142 advanced NSCLC patients.
| N = 142 (100%) | ||
|---|---|---|
| Age | Mean (Standard Deviation) | 66 (10.6) |
| Sex | male | 85 (60%) |
| female | 57 (40%) | |
| ECOG performance status | 0 | 39 (27%) |
| 1 | 86 (61%) | |
| 2 | 14 (10%) | |
| 3 | 3 (2%) | |
| Histology | non-squamous | 96 (68%) |
| squamous | 46 (32%) | |
| Smoking history | smoker | 116 (88%) |
| never-smoker | 16 (12%) | |
| missing | 10 (7%) | |
| TNM stage | IIIA | 6 (4%) |
| IIIB | 8 (6%) | |
| IIIC | 1 (1%) | |
| IV | 127 (89%) | |
| ALK translocation | no | 131 (98%) |
| yes | 3 (2%) | |
| missing | 8 (6%) | |
| EGFR mutation status | wild-type | 130 (93%) |
| mutant | 10 (7%) | |
| missing | 2 (1%) | |
| CNS involvement | no | 112 (79%) |
| yes | 30 (21%) | |
| PD-L1 status | positive | 75 (63%) |
| negative | 44 (37%) | |
| missing | 23 (16%) | |
| PD-L1 status category | <1% | 44 (37%) |
| 1–50% | 39 (33%) | |
| >50% | 35 (30%) | |
| ICB therapy line | 1st line | 40 (28%) |
| 2nd line | 67 (47%) | |
| ≥ 3rd line | 35 (25%) | |
| Immune-checkpoint inhibitor | nivolumab | 79 (55%) |
| pembrolizumab | 52 (37%) | |
| atezolizumab | 11 (8%) | |
| Monotherapy versus combined therapy | ICB monotherapy | 137 (97%) |
| ICB combination therapy | 5 (3%) | |
| Tertiary oncologic center | Salzburg | 50 (35%) |
| Linz | 92 (65%) | |
| Prior/concomitant denosumab application | no | 106 (75%) |
| yes | 36 (25%) | |
| Prior/concomitant anti-VEGF therapy * | no | 125 (88%) |
| yes | 17 (12%) | |
| Prior radiotherapy # | no | 79 (56%) |
| yes | 63 (44%) | |
| Subsequent therapy | no therapy | 85 (60%) |
| taxane-based | 19 (13%) | |
| TKI | 17 (12%) | |
| other | 21 (15%) | |
| Antibiotic treatment during ICB § | no | 80 (56%) |
| yes | 62 (44%) | |
| Antibiotic class | penicillin | 45 (73%) |
| fluoroquinolone | 27 (44%) | |
| cephalosporine | 12 (19%) | |
| carbapenem | 5 (8%) | |
| metronidazole | 5 (8%) | |
| macrolide | 4 (6%) | |
| linezolide | 2 (3%) | |
| Antibiotic treatment indication | empiric antibiotic therapy | 31 (50%) |
| respiratory tract infection | 18 (29%) | |
| perioperative prophylaxis | 5 (8%) | |
| gastrointestinal tract infection | 4 (6%) | |
| biliary tract infection | 2 (3%) | |
| urinary tract infection | 1 (2%) | |
| central venous catheter infection | 1 (2%) | |
ECOG: Eastern Cooperative Oncology Group, EGFR: epidermal growth factor receptor, ALK: anaplastic lymphoma kinase, CNS: central nervous system, PD-L1: programmed cell death ligand 1, ICB: immune-checkpoint blockade, VEGF: vascular endothelial growth factor, TKI: tyrosine kinase inhibitor. * bevacizumab, ramucirumab, or nintedanib. § administration of antibiotics within a time frame of one month before or one month after initiation of immune-checkpoint blockade. # to the primary tumor or metastases.